Search results for "drug withdrawal"

showing 10 items of 15 documents

Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience

2017

The occurrence of thiopurine-related adverse events (AEs) may complicate the management of patients with inflammatory bowel disease (IBD). We aimed to evaluate the tolerability of thiopurines in a current IBD setting.All consecutive patients who started a treatment with azathioprine (AZA) from January 2010 to March 2016 were entered in a prospectively maintained database, and the AEs which led to the permanent discontinuation of the drug were reported.Two hundred and fifty three patients were included. Median total follow-up was 32 months (range: 0.2-75 months). At the end of the study, AZA was discontinued in 160 patients (63.2%). The main reason leading to drug withdrawal was the occurren…

AdultMalemedicine.medical_specialtyNauseaAzathioprineKaplan-Meier EstimateInflammatory bowel disease03 medical and health sciencesDrug withdrawal0302 clinical medicineInternal medicineAzathioprinemedicineHumansCumulative incidenceProspective StudiesAdverse effectMercaptopurinebusiness.industryGastroenterologyNauseaMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurgeryDiscontinuationItalyTolerability030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologymedicine.symptombusinessImmunosuppressive Agentsmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes.

1987

Endocrine responses in seven power athletes were investigated during a 12 week strength training period, when the athletes were taking high doses of androgenic-anabolic steroids, and during the 13 weeks following drug withdrawal. During the use of steroids significant decreases (P less than 0.05 to 0.001) in the serum concentrations of thyroid stimulating hormone, thyroxine, triidothyronine, free thyroxine, and thyroid hormone-binding globulin (TBG) were found, whereas the value of triidothyronine uptake increased (P less than 0.001). In relation to the changes in the thyroid function parameters measured, we suggest that the primary target of androgen action was TBG biosynthesis. In five of…

Adultmedicine.medical_specialtyThyroid HormonesHydrocortisonemedicine.medical_treatmentPhysical Therapy Sports Therapy and RehabilitationSelf Medication03 medical and health sciencesDrug withdrawal0302 clinical medicineAnabolic AgentsThyroid-stimulating hormoneInternal medicinemedicineEndocrine systemHumansOrthopedics and Sports MedicineTestosteroneTestosterone030222 orthopedicsEstradiolbusiness.industryThyroid030229 sport sciencesmedicine.diseaseHormonesPituitary HormonesEndocrinologymedicine.anatomical_structureThyroid functionbusinessAnabolic steroidHormoneSportsThe American journal of sports medicine
researchProduct

Nationwide evaluation of day-to-day clinical pharmacists' interventions in German hospitals.

2015

tudy Objective To describe and evaluate the extent and diversity of nationwide data from clinical pharmacists’ interventions (PIs) in German hospitals. Design Retrospective analysis. Data Source The ADKA-DokuPIK German database, a national anonymous self-reported Internet-based documentation system for routine PIs as well as for medication errors reported by German hospital pharmacists. Measurements and Main Results Data sets from ADKA-DokuPIK entered between January 2009 and December 2012 were analyzed descriptively. A total of 27,610 PIs were entered, mainly by ward-based clinical pharmacists (82.5%). Most of the PIs were performed on surgical wards (37.8%), followed by anesthesiology/int…

Data sourcemedicine.medical_specialtyDatabases Factualbusiness.industryPsychological interventionIntensive care unitlanguage.human_languagelaw.inventionGermanClinical pharmacySafety-Based Drug WithdrawalslawAnesthesiologyGermanyAntithromboticEmergency medicinemedicinelanguageAdverse Drug Reaction Reporting SystemsHumansMedication ErrorsPharmacology (medical)Day to daybusinessPharmacy Service HospitalPharmacotherapy
researchProduct

Mpdz is a quantitative trait gene for drug withdrawal seizures

2004

Physiological dependence and associated withdrawal episodes can constitute a powerful motivational force that perpetuates drug use and abuse. Using robust behavioral models of drug physiological dependence in mice, positional cloning, and sequence and expression analyses, we identified an addiction-relevant quantitative trait gene, Mpdz. Our findings provide a framework to define the protein interactions and neural circuit by which this gene's product (multiple PDZ domain protein) affects drug dependence, withdrawal and relapse.

DrugGenotypePositional cloningmedia_common.quotation_subjectMolecular Sequence DataQuantitative Trait LociPDZ domainGene ExpressionQuantitative trait locusBiologyProtein–protein interactionMiceMice CongenicDrug withdrawalSeizuresmedicineAnimalsGenetic Predisposition to DiseaseCloning MolecularGenemedia_commonGeneticsBehavior AnimalEthanolGeneral NeuroscienceChromosome MappingMembrane ProteinsEmbryo Mammalianmedicine.diseaseSubstance Withdrawal SyndromeMice Inbred C57BLCarrier ProteinsNeuroscienceNature Neuroscience
researchProduct

Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.

2007

Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting res…

DrugTopiramateAdultmedia_common.quotation_subjectmedicine.medical_treatmentIndomethacinNeurological disorderFructoseCentral nervous system diseaseDrug withdrawalPrimary headacheTopiramateProfilaxismedicineHumansmedia_commonbusiness.industryAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaMiddle Agedmedicine.diseaseAnticonvulsantNeurologyHemicrania continuaAnesthesiaGastritisRetreatmentSettore MED/26 - NeurologiaAnticonvulsantsFemaleNeurology (clinical)businessmedicine.drugHeadache
researchProduct

Adverse drug reactions in the oral cavity

2012

Several drugs may have a number of adverse reactions (ADRs) involving the oro-facial region. The dose of the drug and the time required for the reaction to take place are relevant parameters; nonetheless, ADRs mechanisms are not always known and ADRs are not always predictable since aspects other than drug pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. All tissues and many functions of the oral cavity can be affected. In particular, salivary function is fre- quently involved and hypo-salivation is the main manifestation; several mucosal lesions with different morphology (ulcerations, vesiculo- bullous lesions, white lesion…

Drugdrug pharmacodynamicosteonecrosimedicine.medical_specialtyTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche Applicatehypo-salivationPigmentationsPharmacologyOral cavitymucosal lesionDrug withdrawalPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryHumansMedicinemedical liabilityDrug reactionpharmacokineticmedia_commonPharmacologyMouthDose-Response Relationship Drugbusiness.industrybisphosphonates.Mucosal lesionsMouth MucosadrugAdverse reactionmedicine.diseaseDermatologyPharmaceutical PreparationsTastePharmacodynamicsoral cavityadverse drug reaction oral cavityMouth DiseasesSalivationbusiness
researchProduct

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm…

2020

Background and objectives: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. Material and methods: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naive patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). Results: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescrib…

Drugmedicine.medical_specialtyHistologyBiologicmedia_common.quotation_subjectDiscontinuationDermatologyBiologic treatmentPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesDrug withdrawal0302 clinical medicinePsoriasisUstekinumabTrendmedicinePsoriasisMedical prescriptionIntensive care medicineAdverse effectmedia_commonbusiness.industryBiobadadermmedicine.diseaseDiscontinuationTreatment030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

Drug-Induced Respiratory Disease in Connective Tissue Diseases

2004

Publisher Summary This chapter discusses drug-induced respiratory disease in connective tissue diseases. Drug-induced lung diseases (DILDs) vary in severity from mild to life threatening. Generally, DILDs subside upon drug discontinuance, and leave permanent sequelae in a minority of patients. Less frequently, DILDs persist unabated, or progress despite drug withdrawal, requiring specific management. Drugs used in connective tissue diseases (CTDs) can produce a constellation of pulmonary and systemic reactions. These can mimic pulmonary involvement from CTD, a systemic disease, or an infection, and are difficult to prevent, predict, and diagnose. Maintaining a high index of suspicion enable…

Drugmedicine.medical_specialtySystemic diseaseLungbusiness.industrymedia_common.quotation_subjectRespiratory diseaseConnective tissuemedicine.diseaseDrug withdrawalSystemic reactionmedicine.anatomical_structureImmunologymedicineIntensive care medicinebusinessmedia_common
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression.

1995

Peroxisome proliferators (PPs) are non-genotoxic carcinogens in rodents. Their reversible effects on rat liver have been studied with ciprofibrate and fenofibrate. We found that with the hypolipemic drug fenofibrate a pause of 28 days is sufficient for a return to normal status, whereas with the highly potent PP ciprofibrate, the stimulation of ACO mRNA levels remains after its withdrawal. We investigated the effects of the renewal of the treatment with PPs on other peroxisomal parameters and proto-oncogene expression using Wistar rats. Interestingly, c-myc expression was enhanced even upon drug withdrawal, and was more stimulated by the second exposure to ciprofibrate, while c-fos expressi…

Malemedicine.medical_specialtyTime FactorseducationStimulationMitochondria LiverBiologyBiochemistryMicrobodiesDrug withdrawalClofibric AcidFenofibrateInternal medicineProto-Oncogene ProteinsGene expressionmedicineAnimalsRats WistarCarcinogenPharmacologyFenofibrateOncogeneFibric AcidsPeroxisomemedicine.diseaseRatsEndocrinologyLiverMicrosomes LiverCiprofibrateAcyl-CoA OxidaseOxidoreductasesmedicine.drugBiochemical pharmacology
researchProduct